← All trials
NCT05432284
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2023
- Primary completion
- Nov 30, 2025
- Completion date
- Nov 30, 2025
- First posted
- Jun 27, 2022
- Last posted
- Nov 9, 2022
- Enrollment
- 32
- Arms / groups
- 9 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Johns Hopkins UniversityLead sponsor
- National Institute on Drug Abuse (NIDA)Collaborator
- Johns Hopkins UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.